Voyageur Pharmaceuticals (TSE:VM)
:VM
Want to see TSE:VM full AI Analyst Report?
Top Page
Voyageur Pharmaceuticals
(VM)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.10
▼(-41.18% Downside)
Action:ReiteratedDate:04/25/26
The score is weighed down primarily by weak financial performance—large losses, deeply negative margins, and significant cash burn—despite strong revenue growth. Technicals add additional pressure with a clear downtrend and negative momentum indicators. Valuation offers limited support because the company is loss-making and pays no dividend.
Positive Factors
Revenue Growth
Sustained TTM revenue growth of ~165% signals meaningful commercialization progress beyond one-off sales. Over the next 2–6 months, this trend supports scale economies if maintained, validating product-market fit and providing a foundation to improve margins as fixed costs are absorbed.
Negative Factors
Negative margins
Deeply negative gross margins and large operating losses indicate the business is not yet covering variable or fixed costs. Over months this undermines internal funding ability, requires continual external financing, and delays the onset of sustainable unit economics until margins materially improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained TTM revenue growth of ~165% signals meaningful commercialization progress beyond one-off sales. Over the next 2–6 months, this trend supports scale economies if maintained, validating product-market fit and providing a foundation to improve margins as fixed costs are absorbed.
Read all positive factors
Voyageur Pharmaceuticals (VM) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$18.75M
Dividend YieldN/A
Average Volume (3M)72.03K
Price to Earnings (P/E)―
Beta (1Y)-0.59
Revenue GrowthN/A
EPS Growth-28.29%
CountryCA
Employees49
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding178,586,980
10 Day Avg. Volume61,621
30 Day Avg. Volume72,034
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)21.82
Price to Sales (P/S)2339.21
P/FCF Ratio-9.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Voyageur Pharmaceuticals Business Overview & Revenue Model
Company Description
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in th...
How the Company Makes Money
Revenue model and key streams are not publicly available in sufficient detail to describe factually. null...
Voyageur Pharmaceuticals Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 11.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.22M | -1.57K | -2.19K | -2.91K | -2.25K |
| EBITDA | -3.53M | -1.71M | -1.22M | -1.75M | -2.05M |
| Net Income | -3.53M | -1.71M | -1.40M | -1.75M | -2.05M |
Balance Sheet | |||||
| Total Assets | 3.11M | 2.60M | 2.16M | 2.10M | 2.57M |
| Cash, Cash Equivalents and Short-Term Investments | 267.05K | 165.57K | 2.08K | 31.56K | 812.97K |
| Total Debt | 40.00K | 40.00K | 40.00K | 25.52K | 42.08K |
| Total Liabilities | 1.85M | 2.15M | 727.88K | 630.83K | 660.64K |
| Stockholders Equity | 1.25M | 449.96K | 1.44M | 1.46M | 1.91M |
Cash Flow | |||||
| Free Cash Flow | -2.89M | -302.29K | -991.25K | -2.00M | -2.09M |
| Operating Cash Flow | -2.89M | -302.29K | -991.25K | -1.72M | -1.65M |
| Investing Cash Flow | -270.02K | -165.96K | -174.72K | -274.15K | -432.08K |
| Financing Cash Flow | 3.26M | 631.73K | 1.14M | 1.21M | 2.90M |
Voyageur Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | C$34.26M | -3.74 | 7.78% | ― | 22.08% | ― | |
59 Neutral | C$38.24M | -3.31 | -19.10% | ― | 7.54% | 24.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | C$25.91M | -19.43 | -71.80% | ― | -7.53% | 41.77% | |
47 Neutral | C$18.24M | -7.21 | -68.32% | ― | 0.08% | 30.81% | |
45 Neutral | C$9.23M | 5.19 | ― | ― | -25.05% | 67.74% | |
41 Neutral | C$18.75M | -11.39 | -256.01% | ― | ― | -28.29% |
* Healthcare Sector Average
TSE:VM
Voyageur Pharmaceuticals
0.11
-0.07
-40.00%
TSE:LABS
MediPharm Labs
0.09
0.00
0.00%
TSE:PCLO
PharmaCielo
0.06
0.00
0.00%
TSE:ROMJ
Rubicon Organics
0.51
0.03
6.25%
TSE:AVCN
Avicanna
0.15
-0.11
-42.00%
TSE:INNO
InnoCan Pharma
5.76
-4.64
-44.62%
Voyageur Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Voyageur Pharmaceuticals Launches Up to $7.5 Million Private Placement to Advance Contrast Media Projects
Positive
Mar 25, 2026
Voyageur Pharmaceuticals has launched a non-brokered private placement to raise between $4 million and $7.5 million through a combination of common share units and flow-through shares priced at $0.13 and $0.17 respectively. Each unit includes a co...
Business Operations and StrategyProduct-Related Announcements
Voyageur Advances Vertically Integrated Barium and Iodine Contrast Media Strategy
Positive
Mar 16, 2026
Voyageur Pharmaceuticals has outlined a strategic roadmap to build a vertically integrated supply chain for barium and iodine contrast media, targeting vulnerabilities in the fast-growing diagnostic imaging market. The company is advancing two ban...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Voyageur Confirms High-Purity Barite, Advances to Health Canada Trial
Positive
Mar 4, 2026
Voyageur Pharmaceuticals has confirmed that barium sulfate sourced from its Frances Creek property meets and exceeds pharmaceutical-grade standards, with independent SGS testing showing an average purity of 98.8% BaSO4 and full compliance with USP...
Business Operations and StrategyPrivate Placements and Financing
Voyageur Pharmaceuticals Secures Bayer Collaboration to Advance Iodine Contrast Supply
Positive
Feb 23, 2026
Voyageur Pharmaceuticals has signed a collaboration and funding agreement with Bayer that could provide up to USD 2.35 million in milestone-based funding to advance a potential iodine production project in Oklahoma for use in contrast media drugs....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.